Compare HTOO & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTOO | NCNA |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | Ireland | United Kingdom |
| Employees | 131 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.8M |
| IPO Year | N/A | 2017 |
| Metric | HTOO | NCNA |
|---|---|---|
| Price | $3.18 | $2.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.6K | ★ 42.0K |
| Earning Date | 02-28-2023 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4,832.46 | N/A |
| Revenue Next Year | $81.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.03 |
| 52 Week High | $12.63 | $10.00 |
| Indicator | HTOO | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.30 | 63.80 |
| Support Level | $2.92 | $2.07 |
| Resistance Level | $3.64 | $3.80 |
| Average True Range (ATR) | 0.21 | 0.18 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 52.91 | 96.88 |
Fusion Fuel Green PLC is a provider of full-service energy engineering and advisory solutions, specializing in green hydrogen and industrial gas applications. It offers a broad portfolio of services, including the design, supply, installation, and maintenance of energy systems, as well as the transport and distribution of liquefied petroleum gas. The company serves a diverse customer base spanning commercial buildings, mixed-use developments, heavy industries, and food service sectors. The group currently derives revenue by providing comprehensive solutions for the liquefied petroleum gas (LPG) industry, which includes the supply, installation, and maintenance of LPG systems, as well as transportation and delivery of LPG in both bulk and cylinder formats.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.